Recently, the first two B cell maturation antigen (BCMA)-targeted CAR T for MM were approved, idecabtagene vicleucel (ide-cel)2 and ciltacabtagene autoleucel (cilta-cel)3. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.